Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking

Scott Stern, Manuel Trajtenberg

NBER Working Paper No. 6851
Issued in December 1998
NBER Program(s):Economics of Aging, Health Care

This paper studies the consequences of physician authority on pharmaceutical prescribing. Physicians engage in a costly process of particular conditions and characteristics. The relative efficiency of this matching process results from the diagnostic skill of the physician along with the investments made by the doctor in learning about different drugs. While the underlying level of physician skill or knowledge cannot be observed, differences among physicians in terms of these attributes are reflected in their prescribing behavior. We provide evidence for two major findings regarding the exercise of physician authority in this context. First, there is substantial variation in the degree to which physician prescribing is concentrated (i.e., some physicians prescribe a more diverse portfolio of drugs than others). Second, this concentration is correlated with observable drug characteristics. In particular, concentrated prescribers tend to prescribe drugs with high levels of advertising, low prices, and high (lagged) market shares. Our empirical results provide evidence for the importance of both physician effort and diagnostic ability in the prescribing process. In particular, physicians who differentiate among their patients more finely are more likely to have less concentrated prescribing portfolios and to be less sensitive to information sources which promote the use of drugs for the

download in pdf format
   (1340 K)

email paper

A non-technical summary of this paper is available in the May 1999 NBER Digest.  You can sign up to receive the NBER Digest by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w6851

Users who downloaded this paper also downloaded* these:
Ellickson, Stern, and Trajtenberg Patient Welfare and Patient Compliance -- An Empirical Framework for Measuring the Benefits from Pharmaceutical Innovation
Branstetter, Chatterjee, and Higgins w17188 Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
Levine Taub, Kolotilin, Gibbons, and Berndt w16823 The Diversity of Concentrated Prescribing Behavior: An Application to Antipsychotics
Cockburn, Henderson, and Stern w7359 The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research
Ellickson, Stern, and Trajtenberg w6890 Patient Welfare and Patient Compliance: An Empirical Framework for Measuring the Benefits from Pharmaceutical Innovation
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us